Recent Updates
Recently added Catalysts
IVVD Negative Sentiment Score: 20/100

INVIVYD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI

Key Takeaway: Kahn Swick & Foti, LLC has initiated an investigation into Invivyd, Inc. regarding potential breaches of fiduciary duties by its officers and directors. This follows a securities class action lawsuit that alleges the company failed to disclose critical information about its lead product candidate ADG20. The investigation focuses on compliance with state and federal laws amidst these ongoing legal challenges. Invivyd, formerly known as Adagio Therapeutics, has faced scrutiny over its COVID-19 treatment efficacy claims.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investigation initiated due to alleged breach of fiduciary duties by Invivyd officers and directors.
  • Class action lawsuit pending against the company for failing to disclose material information.
  • Former Attorney General's involvement may indicate serious legal concerns.

Full Press Release Details

NEW ORLEANS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI).
Adagio, formed in June 2020 to develop drugs for the treatment and prevention of COVID-19, conducted its initial public offering (“IPO”) in August 2021. In September 2022, Adagio announced that it was changing its corporate name to Invivyd, Inc. and that its stock would trade under “IVVD.”
On December 14, 2021, Adagio disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains pending.
KSF’s investigation is focusing on whether Invivyd’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Invivyd shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-ivvd/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the recent investigation regarding Invivyd, Inc.?

Kahn Swick & Foti, LLC is investigating Invivyd, Inc. for possible breaches of fiduciary duties.

What prompted the investigation into Invivyd?

The investigation follows a securities lawsuit alleging failure to disclose important information.

When did Adagio change its name to Invivyd?

Adagio changed its name to Invivyd, Inc. in September 2022.

What issue was found with Invivyd's ADG20 product?

ADG20 was found to be 300 times less effective against the Omicron variant.

How can investors contact KSF regarding the investigation?

Investors can call 1-833-938-0905 or email Lewis Kahn at lewis.kahn@ksfcounsel.com.

Last updated: Aug 10, 2023